ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
41.07
0.02%
US Tech 100
21,038.00
0.79%
S&P 500
6,090.27
0.25%
US Dollar vs CAD
1.41575
0.00%
Bitcoin
100,088.71
0.17%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. RAPT Therapeutics Inc (RAPT) Share Price

RAPT Therapeutics Inc

RAPT Therapeutics Inc (RAPT)

NASDAQ
1.055
0.02
(1.93%)
Closed December 08 3:00PM
Delayed by 15 minutes
1.06
0.005
(0.47%)
After Hours: 5:05PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.06
Bid
0.97
Ask
1.27
Volume
369,978
0.9212 Day's Range 1.10
1.00 52 Week Range 27.35
Market Cap
37.056M
Previous Close
1.035
Open
1.03
Last Trade
1000
@
1.06
(formt)
Last Trade Time
Financial Volume
US$ 387,895
VWAP
1.0484
Average Volume (3m)
561,114
Shares Outstanding
34,958,253
Dividend Yield
-
PE Ratio
-0.31
Earnings Per Share (EPS)
-3.34
Revenue
-
Net Profit
-116.8M

About RAPT Therapeutics Inc

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rapt.com
Headquarters
Dover, Delaware, USA
Founded
-
RAPT Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPT. The last closing price for RAPT Therapeutics was US$1.04. Over the last year, RAPT Therapeutics shares have traded in a share price range of US$ 1.00 to US$ 27.35.

RAPT Therapeutics currently has 34,958,253 shares outstanding. The market capitalization of RAPT Therapeutics is US$36.18 million. RAPT Therapeutics has a price to earnings ratio (PE ratio) of -0.31.

Ask ADVFN Intelligence (AI)

RAPT Latest News

More News

Form 8-K - Current report

November 15 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

November 12 2024
GlobeNewswire Inc.

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

November 11 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 08 2024
Edgar (US Regulatory)

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

August 08 2024
GlobeNewswire Inc.

Form 8-K - Current report

July 19 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

May 23 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.17-13.82113821141.231.27951.023698801.10880503CS
4-2.04-65.80645161293.13.14110752301.47734389CS
12-0.89-45.6410256411.953.3215611141.70553533CS
26-3.14-74.76190476194.24.2114438982.20467209CS
52-16.08-93.815635939317.1427.3517272037.92821972CS
156-29.03-96.477234961830.0940.74147781014.29853429CS
260-25.43-95.998489996226.4951.2095140453018.99971201CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
UPCUniverse Pharmaceuticals Inc
US$ 3.38
(221.90%)
93.07M
LIFWMSP Recovery Inc
US$ 3.2461
(104.16%)
29.08M
GXAIGaxos ai Inc
US$ 2.5801
(81.70%)
145.87M
SBETSharpLink Gaming Inc
US$ 0.9116
(73.97%)
27.08M
HCTIHealthcare Triangle Inc
US$ 1.165
(68.38%)
4.34M
ORISOriental Rise Holdings Ltd
US$ 3.6833
(-93.42%)
27.51M
LICNLichen China Limited
US$ 0.4895
(-76.91%)
185.96M
MYNAMynaric AG
US$ 0.499246
(-64.59%)
3.6M
CEROCERo Therapeutics Holdings Inc
US$ 0.1146
(-40.16%)
37.87M
BTCTBTC Digital Ltd
US$ 10.50
(-32.95%)
3.26M
SMXSMX Security Matters Public Company
US$ 0.4879
(64.06%)
440.04M
SOUNSoundHound AI Inc
US$ 15.01
(12.60%)
215.93M
LICNLichen China Limited
US$ 0.4895
(-76.91%)
185.96M
NVDANVIDIA Corporation
US$ 142.44
(-1.81%)
185.41M
SVMHSRIVARU Holding Ltd
US$ 0.0293
(-16.29%)
160.45M

RAPT Discussion

View Posts
glenn1919 glenn1919 1 week ago
RAPT.........................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
RAPT under $3
👍️0
Monksdream Monksdream 3 months ago
RAPT new 52 week low
👍️0
Monksdream Monksdream 4 months ago
RAPT new 52 low
👍️0
Monksdream Monksdream 5 months ago
RAPT under $4
👍️0
Monksdream Monksdream 7 months ago
RAPT new 52 week
👍️0
Monksdream Monksdream 7 months ago
RAPT under $10
👍️0
tickersym tickersym 10 months ago
Bargin prices!! Lets go!!
👍️0
Stockexpertpro Stockexpertpro 10 months ago
RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
👍️0
StockLogistics StockLogistics 2 years ago
Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

“8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
👍️0
StockLogistics StockLogistics 3 years ago
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 years ago
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 years ago
15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.
👍️0
StockLogistics StockLogistics 3 years ago
A ton of insider buying last week
👍️0
StockLogistics StockLogistics 3 years ago
Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
👍️0
Glider549 Glider549 3 years ago
It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.
👍️0
weasel4339 weasel4339 3 years ago
It's way up after hours bud
👍️0
Glider549 Glider549 3 years ago
Can't believe some of you did not take profits near the close.
Greed will kill ya.
👍️0
pennyfinder pennyfinder 3 years ago
Will do
👍️0
weasel4339 weasel4339 3 years ago
I'll keep n eye out. Let me knoe if u hear something about the price
👍️0
pennyfinder pennyfinder 3 years ago
Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
👍️0
weasel4339 weasel4339 3 years ago
This considered dilution?
👍️0
pennyfinder pennyfinder 3 years ago
LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
👍️0
make it happen make it happen 3 years ago
Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
👍️0
pennyfinder pennyfinder 3 years ago
Offering AH or tomorrow pre
👍️0
make it happen make it happen 3 years ago
Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M
👍️0
StockLogistics StockLogistics 3 years ago
This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
👍️0
Roadtojourney Roadtojourney 5 years ago
Not even 6 months old and already offering??
👍️0
crudeoil24 crudeoil24 5 years ago
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
👍️0
crudeoil24 crudeoil24 5 years ago
42.00 > hod.

RAPT
👍️0
crudeoil24 crudeoil24 5 years ago
29.01 x 30.00

RAPT
👍️0
crudeoil24 crudeoil24 5 years ago
Multiple Nasdaq circuit breakers halts today

RAPT
👍️0
crudeoil24 crudeoil24 5 years ago
7.7M shares trading float >

RAPT
👍️0

Your Recent History

NASDAQ
RAPT
RAPT Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved